ClinicalTrials.gg
RecruitingNCT05682417SCAMUpdated Jun 4, 2024

Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa

An interventional study of Body Map Assessment Tool: MOVE Tool and PAQ questionnaire in Anorexia Nervosa, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to female participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
15 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Anorexia Nervosa with a site in France — 16 open to participants now, 21 under way, 1 of them phase 3. Anorexia Nervosa · France.

Planned enrollment
28th of 48
42 · median 56
Started
2024
with 6 others
No phase
45 of 79
8 open now
Primary completion
2026-09
later than 2 of 20 live
Registered
64th of 79
by date
Lead sponsor
4 of 79
Hospices Civils de Lyon

Among the 79 studies in Anorexia Nervosa with a site in France, this one is the 28th largest by planned enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2024, is one of 45 with no phase, reaches primary completion later than 2 of the 20 other live ones, and was the 64th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

16 of the 79 studies in Anorexia Nervosa with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 15 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Anorexia Nervosa with a site in France, or all of them as a file.
02

Study summary

Anorexia nervosa is a predominantly female eating disorder that most often appears in adolescence. The latter leads to strict and voluntary food deprivation for several months or even years. The lifetime prevalence of anorexia is 1.4% in women and 0.2% in men.

Ultimately, only half of people treated for anorexia nervosa in adolescence recover, 30% simply improve, 21% suffer from chronic disorders and 5 to 6% die. At the same time, between a quarter and half of patients abandon their current treatment, including during hospitalization. Relapses occur during the evolution of anorexia nervosa. Even more worrying, mortality is highest the year following the patient's discharge from hospital. This appears to be due to somatic complications in more than half of cases (most often cardiac arrest), to suicide in 27% of cases.

Researchers are still trying to clarify the mechanisms involved in the emergence and persistence of this disorder. The objective is to obtain more verified and faster cures. However, the obstacles to successful treatment are mainly due to the denial of disorders and thinness.

From a neurocognitive perspective, the representation one has of one's body is underpinned by two types of representations, i.e. body image and body schema.

It has long been shown that body image is altered in anorexia nervosa. More recently, authors have shown that the distortion of the body representation was however more extensive and also affected the body schema. Patients find themselves too fat despite obvious thinness and move through space as if this were really the case.

Worryingly, these distortions in bodyschema seem to persist after therapeutic management. Despite the potential role of body-scheme distortions in maintaining the disorder, as well as the risk of relapse, the difficulties in assessing body-scheme are significant. Indeed, recovery in these pathologies is often determined according to the Body Mass Index, self-declaration and questionnaires evaluating body image, again limiting the verification of the resorption of distortions in the body schema.

Investigators have therefore developed the systematic, ergonomic and simplified evaluation of the body schema in patients suffering from anorexia nervosa at the time of diagnosis in an expert center, but also during follow-up evaluations thanks to the use of an evaluation platform of the body schema, i.e. the body in brain platform, developed by the LIP/PC2S laboratory and the SATT Linksium which allows the evaluation of the body schema.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • Anorexia nervosa
  • Body image
  • Body distortion
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 15 years old
  • Women
  • Patient with a \<18.5
  • Patient suffering from anorexia nervosa (DSM V, 2013)
  • Patient agreeing to participate in the study with signed (Or whose parents/holder of parental authority have signed the informed consent)
  • Patient affiliated to a Social Security plan or beneficiary of such a plan

Exclusion criteria

Exclusion Criteria:

  • Adult patients protected by a legal protection measure (guardianship, curatorship, etc.)
  • Patients participating in another research that may interfere with this research
  • Patients with acute and co-occurring psychiatric comorbidities (suicidal crisis, delusions)
  • Patients not fluent in French
  • Pregnant, parturient or breastfeeding women (on questioning of the patient)
  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons admitted to a health or social establishment for purposes other than research
  • Patients with any current pathology or history of psychotic disorders, migraine, epilepsy, balance disorders, vertigo, visual disorders, proprioceptive disorders and/or neuromuscular disorders.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Patients with anorexia nervosa according to DSM-5

    Patients over 15 years old, suffering from anorexia nervosa according to DSM-V with a BMI\<18.5 and without psychiatric comorbidities

    Device: Body Map Assessment Tool: MOVE Tool · Other: PAQ questionnaire · Other: F-DFlex questionnaire · Other: BSQ questionnaire · Other: Silhouette testing · Other: Eating Disorder Inventory - 2 · Other: EDEQ questionnaire · Other: STAI questionnaire · Other: BECK questionnaire

Interventions

  • DeviceBody Map Assessment Tool: MOVE Tool

    In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body. Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area.

  • OtherPAQ questionnaire

    This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.

  • OtherF-DFlex questionnaire

    This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.

  • OtherBSQ questionnaire

    The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 ("never") means the problem is not present, up to a score of 6 ("always") which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological.

  • OtherSilhouette testing

    Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.

  • OtherEating Disorder Inventory - 2

    Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer "always", "usually", "often", "sometimes", "rarely" or "never". The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)

  • OtherEDEQ questionnaire

    Or "Eating Disorders Examination - Questionnaire" (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days.

  • OtherSTAI questionnaire

    The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).

  • OtherBECK questionnaire

    Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.

06

What researchers measure

Primary outcomes

  1. Overestimation of the body schema

    Overestimation of the body schema (in percentage) assessed by the body schema assessment platform (MOVE tool, motion assessment in virtual reality). Overestimation of the body schema (percentage of distortion) will be compared to normal values, and then compared with the percentages at T+6 and T+12.

    Time frame: Baseline (T0); 6 months after baseline (T+6); 12 months after baseline (T+12)

Secondary outcomes

  1. Weight/height ratio, expressed by body mass index (BMI)

    This weight(kg)/height(m)2 ratio is measured using a mathematical formula. It will be analyzed using the DSM-V reference table to measure the severity of the disorder. Lightweight: BMI \> or = 17 kg/m2 Moderate: BMI 16-16.99 kg/m2 Severe: BMI: 15-15.99 kg/m2 Extreme: BMI \< 17 kg/m2

    Time frame: Baseline T0; 6 months; 12 months

  2. Body overstatement

    Body overestimation is assessed using the computerized silhouette test. This test presents 27 figures with BMIs ranging from 11 to 40. The patient answers whether or not the figure presented corresponds to his current figure.

    Time frame: Baseline T0; 6 months; 12 months

  3. Alexithymia score

    Alexithymia is assessed with the PAQ questionnaire consisting of 24 questions with 7 degrees of response. (1 strongly disagree - 2 - 3 - 4 Neither agree nor disagree -5 - 6 - 7 strongly agree)

    Time frame: Baseline T0; 6 months; 12 months

  4. Cognitive rigidity score

    The cognitive rigidity score is measured with the D-Flex questionnaire comprising 20 questions. The patient must then respond to the proposed statements using a 6-point scale (Strongly disagree (1), Somewhat disagree (2), Somewhat disagree (3), Somewhat agree (4) , Somewhat agree (5, Strongly agree (6).

    Time frame: Baseline T0; 6 months; 12 months

  5. Body dissatisfaction score

    Body dissatisfaction is measured with the BSQ questionnaire comprising 34 questions rated from 1 (never) to 6 (Always)

    Time frame: Baseline T0; 6 months; 12 months

  6. Eating behavior assessed by the EDI-2 questionnaire

    The eating behavior will be assessed by the EDI-2 questionnaire

    Time frame: Baseline T0; 6 months; 12 months

  7. Eating behavior assessed by the EDE-Q questionnaire

    The eating behavior will be assessed by the EDE-Q

    Time frame: Baseline T0; 6 months; 12 months

  8. Level of anxiety

    Anxiety is measured by STAI questionnaire.

    Time frame: Baseline T0; 6 months; 12 months

  9. Level of Depression

    Depression is measured by BECK questionnaire

    Time frame: Baseline T0; 6 months; 12 months

07

Study locations

1 of 1 sites recruiting
  • Referral Center for Eating Disorders. Neurological Hospital-GH East / Hôpital Neurologique Pierre Wertheimer GHE HCL
    Bron, 69500, France
    Recruiting
    • Lisa FILIPPONE, Neuropsychologist · Contactlisa.filippone@chu-lyon.fr · 0427856022
    • Lisa FILIPPONE, Neuropsychologist · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Sep 2026, 24 months later.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 24 months is below that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 12, 2023
StartEst.
Sep 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05682417
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Sep 2024 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 4, 2024

Study contacts

Lisa FILIPPONE, Neuropsychologist
Contact
lisa.filippone@chu-lyon.fr
0427856022 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion